Akèy › Tit travay › Principal Biostatistician
Principal Biostatistician: Salè H-1B
154 aplikasyon kondisyon travay te itilize tit travay Principal Biostatistician. Salè baz medyàn ofri $137,966; mwatye mitan $119,288–$150,000.
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 48 | $124,322 |
| Biogen Inc. | 19 | $119,496 |
| Regeneron Pharmaceuticals, Inc. | 17 | $149,537 |
| Vertex Pharmaceuticals Incorporated | 10 | $144,925 |
| Incyte Corporation | 10 | $122,500 |
| Parexel International LLC | 6 | $166,856 |
| Edwards Lifesciences LLC | 4 | $118,664 |
| Sandoz Inc. | 3 | $166,951 |
| Cytel Inc. | 3 | $142,726 |
| ClinChoice Inc. | 3 | $153,090 |
| IQVIA RDS Inc. | 3 | $170,000 |
| CSL Behring L.L.C. | 3 | $158,000 |
| Seagen Inc. | 2 | $152,000 |
| Foundation Medicine, Inc. | 2 | $130,863 |
| Servier Bio-Innovation LLC | 2 | $167,250 |
| WCG Clinical, Inc. | 2 | $98,031 |
| Nektar Therapeutics | 2 | $155,584 |
| Adaptimmune LLC | 2 | $175,000 |
| Syneos Health, LLC | 2 | $111,873 |
| Clindata Insight Inc. | 1 | $180,000 |
| Johns Hopkins University | 1 | $105,000 |
| Fortrea Inc. | 1 | $126,110 |
| Janssen Research & Development, LLC | 1 | $145,000 |
| Apellis Pharmaceuticals Inc. | 1 | $154,400 |
| Fortrea Inc. f/k/a LabCorp Drug Development Inc. | 1 | $165,000 |
| Novartis Institutes for BioMedical Research, Inc. | 1 | $106,600 |
| Uswm CT, LLC | 1 | $177,679 |
| Neurocrine Biosciences, Inc. | 1 | $141,856 |
| H2O Clinical, LLC | 1 | $175,000 |
| Ora, Inc. | 1 | $182,490 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo II (kalifye) | $116,482 |
| Nivo III (eksperyans) | $136,219 |
| Nivo IV (plen kompetans) | $144,925 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|---|---|
| FY2023 | 52 | $126,027 |
| FY2024 | 33 | $136,219 |
| FY2025 | 31 | $142,771 |
| FY2026 | 36 | $148,325 |
Vil yo
- East Hanover, NJ43
- Cambridge, MA24
- Boston, MA12
- Tarrytown, NY11
- Wilmington, DE10
- Irvine, CA4
- Basking Ridge, NJ3
- Princeton, NJ3
- Bothell, WA2
- Cary, NC2
- Newton, MA2
- Durham, NC2
- Louisville, KY2
- Horsham, PA2
- King of Prussia, PA2
- Ellicott City, MD1
- Billerica, MA1
- Walnut Creek, CA1
- Jersey City, NJ1
- Seabrook, TX1
- San Francisco, CA1
- Baltimore, MD1
- Millbury, MA1
- Naperville, IL1
- Foster City, CA1
- Matthews, NC1
- Collegeville, PA1
- Raritan, NJ1
- Morrisville, NC1
- Arlington, MA1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).